These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

779 related items for PubMed ID: 17224887

  • 1. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
    Gurbel PA.
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S20-8. PubMed ID: 17224887
    [Abstract] [Full Text] [Related]

  • 2. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
    Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA.
    J Am Coll Cardiol; 2007 Feb 13; 49(6):657-66. PubMed ID: 17291930
    [Abstract] [Full Text] [Related]

  • 3. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
    Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Mielot C, Bali L, Lambert M, Alessi MC, Bonnet JL.
    Thromb Haemost; 2007 Feb 13; 97(2):282-7. PubMed ID: 17264958
    [Abstract] [Full Text] [Related]

  • 4. Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP.
    Moerenhout CM, Claeys MJ, Haine S, Miljoen H, Bosmans JM, Vertessen F, Kluppels K, Van der Planken M, Vrints CJ.
    Am Heart J; 2010 Mar 13; 159(3):434-8. PubMed ID: 20211306
    [Abstract] [Full Text] [Related]

  • 5. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target.
    Gurbel PA, Antonino MJ, Bliden KP, Dichiara J, Suarez TA, Singla A, Tantry US.
    Platelets; 2008 Dec 13; 19(8):595-604. PubMed ID: 19012177
    [Abstract] [Full Text] [Related]

  • 6. Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists.
    Angiolillo DJ, Suryadevara S, Capranzano P, Zenni MZ, Guzman LA, Bass TA.
    Catheter Cardiovasc Interv; 2009 Jan 01; 73(1):1-14. PubMed ID: 19089929
    [Abstract] [Full Text] [Related]

  • 7. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
    Wang ZJ, Zhou YJ, Liu YY, Yu M, Shi DM, Zhao YX, Guo YH, Cheng WJ, Jia de A, Cao Z, Nie B, Ge HL, Yang SW, Yan ZX.
    Thromb Res; 2009 May 01; 124(1):46-51. PubMed ID: 19041120
    [Abstract] [Full Text] [Related]

  • 8. What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention?
    Steinhubl S, Berger P.
    Am Heart J; 2003 Jun 01; 145(6):971-8. PubMed ID: 12796751
    [Abstract] [Full Text] [Related]

  • 9. Platelet activation and progression to complications.
    Kereiakes DJ, Michelson AD.
    Rev Cardiovasc Med; 2006 Jun 01; 7(2):75-81. PubMed ID: 16915126
    [Abstract] [Full Text] [Related]

  • 10. Platelet monitoring for PCI: is it really necessary?
    Tantry US, Gurbel PA.
    Hamostaseologie; 2009 Nov 01; 29(4):368-75. PubMed ID: 19882080
    [Abstract] [Full Text] [Related]

  • 11. Platelet reactivity in patients with subacute stent thrombosis compared with non-stent-related acute myocardial infarction.
    Lev EI, Alviar CL, Arikan ME, Dave BP, Granada JF, DeLao T, Tellez A, Maresh K, Kleiman NS.
    Am Heart J; 2007 Jan 01; 153(1):41.e1-6. PubMed ID: 17174635
    [Abstract] [Full Text] [Related]

  • 12. Platelet function testing and implications for clinical practice.
    Collet JP, Montalescot G.
    J Cardiovasc Pharmacol Ther; 2009 Sep 01; 14(3):157-69. PubMed ID: 19721130
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
    Antman EM, Wiviott SD, Murphy SA, Voitk J, Hasin Y, Widimsky P, Chandna H, Macias W, McCabe CH, Braunwald E.
    J Am Coll Cardiol; 2008 May 27; 51(21):2028-33. PubMed ID: 18498956
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Controversies of oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.
    Rajagopal V, Bhatt DL.
    Semin Thromb Hemost; 2004 Dec 27; 30(6):649-55. PubMed ID: 15630671
    [Abstract] [Full Text] [Related]

  • 19. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP.
    Postgrad Med; 2009 Jan 27; 121(1):59-72. PubMed ID: 19179814
    [Abstract] [Full Text] [Related]

  • 20. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
    Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA, Working Group on High On-Treatment Platelet Reactivity.
    J Am Coll Cardiol; 2010 Sep 14; 56(12):919-33. PubMed ID: 20828644
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.